Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy.
NiKang Therapeutics is a biotech company focused on discovering and developing small molecule oncology medicines.
New Equilibrium Biosciences provides a platform that reveals opportunities for structure-based design by learning biophysics with AI.
Graphite Bio is a next-generation gene editing company that is driven to apply our breakthrough technology.
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product.
DTx Pharma is a biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease.
Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Vividion is a developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses.
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
Kira Pharmaceuticals is a Biotechnology Research Company.
Locana develops RNA-targeting gene therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.
LianBio aims to develop and accelerate availability of paradigm-shifting medicines to patients in China.
AavantiBio is a biopharmaceutical company that provides gene transfer and gene editing therapies to treat genetic diseases.
Saniona is a research and development company with low burn rate, a world class team and high ambitions.
Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.
PMV Pharmaceuticals is a developer of p53-targeted small molecule drugs for the treatment of cancer.
Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.
Akouos is a biotechnology company focusing on restoring and preserving hearing.
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Quench Bio is a developer of gasdermin biology drugs designed to treat severe inflammatory diseases.
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.
Peloton Therapeutics, a biotech company based in Dallas, is involved in discovering and developing novel drugs for cancer treatments.
RA Capital Management has invested in 467 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Medical. The firm invests across 12 different industry categories.
Among tracked funding rounds, LianBio received $310.0M in a Series A round. RA Capital Management's total known invested capital is $56.7B.
RA Capital Management's average investment size is $123.5M across its portfolio of 467 companies.
Recent RA Capital Management portfolio additions include Imara, Bolt Biotherapeutics, NiKang Therapeutics, New Equilibrium Biosciences, Graphite Bio. These companies were founded in 2020 or later.